Cite
Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants.
MLA
Zhongfeng Ye, et al. “Monovalent SARS-COV-2 MRNA Vaccine Using Optimal UTRs and LNPs Is Highly Immunogenic and Broadly Protective against Omicron Variants.” Proceedings of the National Academy of Sciences of the United States of America, vol. 120, no. 52, Dec. 2023, pp. 1–12. EBSCOhost, https://doi.org/10.1073/pnas.2311752120.
APA
Zhongfeng Ye, Bonam, S. R., McKay, L. G. A., Plante, J. A., Walker, J., Yu Zhao, Changfeng Huang, Jinjin Chen, Chutian Xu, Yamin Li, Lihan Liu, Harmon, J., Shuliang Gao, Donghui Song, Zhibo Zhang, Plante, K. S., Griffiths, A., Jianzhu Chen, Haitao Hu, & Qiaobing Xu. (2023). Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants. Proceedings of the National Academy of Sciences of the United States of America, 120(52), 1–12. https://doi.org/10.1073/pnas.2311752120
Chicago
Zhongfeng Ye, Srinivasa Reddy Bonam, Lindsay G. A. McKay, Jessica A. Plante, Jordyn Walker, Yu Zhao, Changfeng Huang, et al. 2023. “Monovalent SARS-COV-2 MRNA Vaccine Using Optimal UTRs and LNPs Is Highly Immunogenic and Broadly Protective against Omicron Variants.” Proceedings of the National Academy of Sciences of the United States of America 120 (52): 1–12. doi:10.1073/pnas.2311752120.